Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Nubeqa

- PMLiVE

Merck, Bayer get FDA priority review for heart failure drug

Target action date set for January 2021

Impetus Digital Fireside Chat with Tom Hsu, VP, Specialty Medicine at Bayer Canada

Tom Hsu, VP of Specialty Medicine at Bayer Canada,  talks about how he got to where he is today and his experience working for Bayer in China, and how that compares to...

Impetus Digital

Bayer symbol

Bayer gets EU nod for prostate cancer drug Nubeqa

Enters an increasingly competitive market

- PMLiVE

Merck, Bayer flesh out vericiguat heart failure data at ACC

Drug reduced rate of cardiovascular deaths and hospitalisations

Bayer symbol

Bayer signs €250m pact with India’s Curadev for STING drugs

Research will focus on auto-immune and inflammatory diseases

Novartis day

Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD

New drug due for launch in Europe in the second quarter

- PMLiVE

J&J gets EMA nod for wider use of Erleada in prostate cancer

Maintains a regulatory lead over rival Xtandi

Bayer symbol

Bayer bulks up in women’s health again with non-hormonal contraceptive deal

If approved candidate would become a first-in-category therapy

Bayer symbol

Bayer extends alliance with Evotec in women’s health

Five-year research agreement focuses on polycystic ovary syndrome

Bayer symbol

Bayer, Merck’s high-risk heart failure drug comes good in phase 3

Significantly reduced the risk of hospitalisation or cardiovascular death

Bristol Myers Squibb logo

BMS scores FDA priority review for Opdivo/Yervoy combo in liver cancer

Possible new treatment for difficult to treat cancer type

- PMLiVE

Bayer’s Vitrakvi scores first EU tumour-agnostic drug approval

Will likely face competition soon from rival Rozlytrek

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links